Global Biotechnology Industry 2006

Publication Date	June 2006
Publisher	Cygnus
Product Type	Report
Pages	32
ISBN Number	not applicable
Product Code	CYG00006

Price

£550.00
approximately: $971 | €697

OTHER ($971 | €697)

Order above formats by FAX

Summary

The global biotechnology industry is estimated to be about USD34.9 billion by the end of June 2006, posting a 11% increase when compared with the biotech industry as a whole, which was at an estimated USD31.5 billion in June, 2005. The Global Biotechnology Insight examines the Biotechnology industry overview covering major markets like North America,Asia Pacific,Europe. This Report will help readers to know the global Biotechnology industry scenario in 2006 and also performance of major players in the same period. Industry wise Mergers and Acquisions will give the nature of consolidation that respective industries have gone through in the same period providing future outlook of Global biotechnology industry in the near future.

Content

1. Industry Overview
2. Major Markets
- 2.1 Economy
- 2.2 North America
- 2.3 Europe
- 2.4 Asia Pacific
3. Major Players
- 3.1 Introduction
- 3.2 Novartis
- 3.3 Amgen
- 3.4 Genentech
- 3.5 MedImmune
- 3.6 Genzyme
- 3.7 Gilead Sciences
- 3.8 Serono SA
- 3.9 Biogen Idec
- 3.10 Millenium Pharmaceutical Inc
- 3.11 Invitrogen
4. Mergers And Acquisitions
- 4.1 Introduction
- 4.2 Major Disclosed Deals
- 4.3 Undisclosed Deals
- 4.4 Some Major Deals
- 4.5 Trends of the deals
5. Future Outlook
List Of Figures
- Figure 2.1: Global Real GDP Growth Rate
- Figure 2.2: Real GDP Growth Rate in the US
- Figure 2.3: Real GDP Growth Rate in Canada
- Figure 2.4: Real GDP Growth Rate in EU 25
- Figure 2.5: Real GDP Growth Rate in Japan
- Figure 2.6: Real GDP Growth Rate in China
- Figure 2.7: Real GDP Growth Rate in India
- Figure 2.8: Important PIPEs during first quarter 2006
- Figure 2.9: Various sources of financing First Quarter 2006
- Figure 5.1: Project share of crops in world GM cultivation 2006
List Of Tables
- Table 1.1: Some outstanding funds raised through IPOs Jan-March 2006
- Table 1.2: Major drugs approved by FDA during Jan-June 2006
- Table 1.3: Some important drugs in pipeline
- Table 1.4: Some important government R&D Funding Jan-June 2006
- Table 2.1: Selected venture financings during first half 2006
- Table 2.2: Noteworthy Follow-ons during first quarter 2006
- Table 2.3: Funds raised by few companies in European Market Jan-June 2006
- Table 3.1: Half Yearly Performance of Top 10 Companies
- Table 3.2: Novartis H1 2005 - H1 2006
- Table 3.3: Amgen H1 2005 - H1 2006
- Table 3.4: Genetech H1 2005 - H1 2006
- Table 3.5: MedImmune H1 2005 - H1 2006
- Table 3.6: Genzyme H1 2005 - H1 2006
- Table 3.7: Gilead Sciences H1 2005 - H1 2006
- Table 3.8: Serono H1 2005 - H1 2006
- Table 3.9: Biogen H1 2005 - H1 2006
- Table 3.10: Millenium H1 2005 - H1 2006
- Table 3.11: Invitrogen H1 2005 - H1 2006
- Table 4.1: Disclosed deals during the first half of 2006
- Table 4.2: Undisclosed deals during the first half of 2006